Omeros opened lower at $17.90, compared with its previous close of $18.15. In the last trading session, the stock traded between $17.38 and $18.13. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Omeros is now worth
$ 219.78
Giving a profit of
$ 119.78 (119.78%)
Note: Past profits do not guarantee future returns.
Rating from 3 Analysts
Today's Change
$-0.15 (-0.83%)
Day High
$18.13
Day Low
$17.38
Day Open
$17.90
Prev Close
$18.15
Volume
6,15,172
1W Return
-1.08%
1M Return
-8.40%
3M Return
32.25%
6M Return
25.35%
1Y Return
161.25%
Market Cap ($ Mn)
1,303
PE Ratio
15.25
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-4.80%
EPS (TTM)
$0.18
1 Week
-1.08%
1 Month
-8.40%
3 Months
32.25%
6 Months
25.35%
9 Months
60.28%
Pomerantz investigates Omeros over EMA rejection claims
Pomerantz LLP is investigating Omeros Corporation for potential securities fraud related to EMA drug reviews. Stock fell 19.12% to $8.67 on June 26, 2026, after initial CHMP negative opinion on narsoplimab. Shares dropped another 13.78% to $16.20 on October 16, 2026, following re-examination negative opinion. The investigation focuses on whether officers engaged in unlawful business practices or fraud.
2 days agoPomerantz investigates Omeros over narsoplimab regulatory disclosures
Pomerantz LLP is investigating Omeros Corp for potential securities fraud related to regulatory disclosures. The probe follows negative CHMP opinions on narsoplimab for TA-TMA treatment in June and October 2026. Shares dropped 19.12% to $8.67 on June 26, 2026, after the initial regulatory setback. A subsequent 13.78% decline to $16.20 occurred on October 16, 2026, following a re-examination failure.
9 days agoOmeros shares fall on negative EU opinion for narsoplimab
Omeros shares fell 2.61% to $18.30 following the EMA's negative opinion on narsoplimab. The CHMP upheld its negative stance after re-examination, citing data handling issues. Q2 YARTEMLEA gross revenue reached $32.2 million, up 190% from Q1. Omeros plans to end its compassionate-use program in Europe due to rising US demand.
27 days agoOmeros Q2 Results: Adj. EPS $0.02 beats $(0.27) estimate
Omeros reported Q2 adjusted EPS of $0.02, beating the $(0.27) estimate by 107.41%. Sales of $28.529 million exceeded the $12.700 million consensus by 124.64%, marking a significant YoY improvement from a loss of $0.43 per share.
3mo agoPomerantz probes Omeros after EMA rejects narsoplimab
Pomerantz LLP is investigating Omeros Corporation for potential securities fraud after the EMA's CHMP rejected the marketing authorization for narsoplimab. The negative opinion caused Omeros shares to fall 19.12% to $8.67 on June 26, 2026. Affected investors are urged to contact the law firm to explore class action options.
3mo agoPomerantz investigates Omeros after CHMP negative opinion
Pomerantz LLP is investigating Omeros Corporation for potential securities fraud following a negative CHMP opinion on its narsoplimab application. The news caused Omeros stock to drop 19.12% on June 26, 2026. Investors are encouraged to contact the firm regarding their rights.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Omeros is now worth
$ 219.78
Giving a profit of
$ 119.78 (119.78%)
Note: Past profits do not guarantee future returns.
